Expert Video - What is the outlook for AML-MRC, tAML, and secondary AML?

Acute myeloid leukemia expert Dr. Sandra Kurtin explains that the outlook for people with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), treatment-related AML (tAML) or secondary myelodysplastic syndrome (secondary MDS) is usually less good than for de novo AML. People who can have a stem cell transplant, also called a bone marrow transplant, have a better outlook with these secondary types of AML. Clinical trials of new treatments may also improve the outlook for AML-MRC, tAML and secondary AML.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.

Please rate this content:

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by educational grants from AbbVie, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.